Affliction class moderates the dementing impact of amyloidopathy.

IF 3 3区心理学 Q3 NEUROSCIENCES

Neuropsychology Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI:10.1037/neu0001021

Donald R Royall, Raymond F Palmer

{"title":"Affliction class moderates the dementing impact of amyloidopathy.","authors":"Donald R Royall, Raymond F Palmer","doi":"10.1037/neu0001021","DOIUrl":null,"url":null,"abstract":"Objective: The treatment of dementia is increasingly likely to focus on dementia-related biomarkers. Unfortunately, there is variability with regard to biomarker-related effects. This analysis tests an algorithm capable of identifying persons adversely impacted by any dementia-related biomarker in this case, amyloidopathy as estimated by positron emission tomography (PET).Method: N = 1,737 subjects of the Alzheimer's disease neuroimaging initiative were assigned to amyloidopathy-affliction classes. Moderation effects were tested by chi-square difference.Results: 39.3% of subjects with (+) PET results were assigned to the afflicted class. The afflicted subjects had greater dementia severity and higher amyloid burdens. These effects persisted at 36 months. Furthermore, the association between amyloid burden and dementia severity was moderated by affliction class. Afflicted nondemented cases with positive PET findings were more likely to convert to clinical \"Alzheimer's disease\" over 48 months, by Cox's F: F(312, 154) = 1.27, p = .05. PET assessed amyloid burden was not related to dementia severity in resilient PET (+) cases.Conclusion: Our approach could allow for more accurate prediction of biomarker effects and guide precision interventions against specific biomarkers. (PsycInfo Database Record (c) 2025 APA, all rights reserved).","PeriodicalId":19205,"journal":{"name":"Neuropsychology","volume":" ","pages":"587-598"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313146/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1037/neu0001021","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The treatment of dementia is increasingly likely to focus on dementia-related biomarkers. Unfortunately, there is variability with regard to biomarker-related effects. This analysis tests an algorithm capable of identifying persons adversely impacted by any dementia-related biomarker in this case, amyloidopathy as estimated by positron emission tomography (PET).

Method: N = 1,737 subjects of the Alzheimer's disease neuroimaging initiative were assigned to amyloidopathy-affliction classes. Moderation effects were tested by chi-square difference.

Results: 39.3% of subjects with (+) PET results were assigned to the afflicted class. The afflicted subjects had greater dementia severity and higher amyloid burdens. These effects persisted at 36 months. Furthermore, the association between amyloid burden and dementia severity was moderated by affliction class. Afflicted nondemented cases with positive PET findings were more likely to convert to clinical "Alzheimer's disease" over 48 months, by Cox's F: F(312, 154) = 1.27, p = .05. PET assessed amyloid burden was not related to dementia severity in resilient PET (+) cases.

Conclusion: Our approach could allow for more accurate prediction of biomarker effects and guide precision interventions against specific biomarkers. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

查看原文本刊更多论文

痛苦等级调节淀粉样变性的痴呆影响。

目的：痴呆症的治疗越来越有可能集中在痴呆症相关的生物标志物上。不幸的是，与生物标志物相关的影响存在可变性。该分析测试了一种算法，该算法能够识别受任何痴呆症相关生物标志物不利影响的人，在这种情况下，通过正电子发射断层扫描（PET）估计淀粉样变性。方法：N = 1,737名阿尔茨海默病神经影像学患者被分配到淀粉样病变-痛苦类。采用卡方差异检验适度效应。结果：39.3% PET结果为（+）的受试者被分配到痛苦类别。受折磨的受试者有更严重的痴呆和更高的淀粉样蛋白负担。这些影响持续了36个月。此外，淀粉样蛋白负担与痴呆严重程度之间的关联因疾病类别而有所缓和。经Cox's F: F(312, 154) = 1.27, p = 0.05计算，PET阳性的非痴呆患者在48个月内更有可能转化为临床“阿尔茨海默病”。在弹性PET（+）病例中，PET评估的淀粉样蛋白负担与痴呆严重程度无关。结论：我们的方法可以更准确地预测生物标志物的作用，并指导针对特定生物标志物的精确干预。（PsycInfo Database Record (c) 2025 APA，版权所有）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropsychology 医学-神经科学

CiteScore

4.10

自引率

4.20%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Neuropsychology publishes original, empirical research; systematic reviews and meta-analyses; and theoretical articles on the relation between brain and human cognitive, emotional, and behavioral function.